| 1 |
31193720 | Endobronchial metastases 20 years after prostate cancer excision. | 2019 |
1 |
| 2 |
29624800 | Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study. | 2018 Jun |
1 |
| 3 |
30624128 | FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. | 2018 Oct - Dec |
2 |
| 4 |
29264358 | Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. | 2017 |
1 |
| 5 |
27390687 | Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. | 2016 |
1 |
| 6 |
27569357 | [Giant Prostate Carcinoma : A Case Report and Long-Term Outcomes in Japanese Patients]. | 2016 Jul |
1 |
| 7 |
25264336 | Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer. | 2015 Mar |
2 |
| 8 |
26070474 | Gonadotropin-releasing hormone antagonist: A real advantage? | 2015 Jul |
1 |
| 9 |
26161141 | Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). | 2015 Jun |
1 |
| 10 |
24440304 | Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. | 2014 Dec |
1 |
| 11 |
24661333 | Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. | 2014 May |
3 |
| 12 |
24756432 | Degarelix: a review of its use in patients with prostate cancer. | 2014 Apr |
1 |
| 13 |
23372607 | Experience with degarelix in the treatment of prostate cancer. | 2013 Feb |
2 |
| 14 |
23620672 | An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. | 2013 |
2 |
| 15 |
22416801 | Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. | 2012 Jul |
2 |
| 16 |
22457321 | The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. | 2012 Jun |
2 |
| 17 |
22748873 | The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. | 2012 Jul |
3 |
| 18 |
23210401 | Prostate cancer: what are the news in hormonal therapy? The role of GnRH antagonists. | 2012 Sep |
2 |
| 19 |
21360851 | Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. | 2011 Mar |
1 |
| 20 |
21788033 | A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. | 2011 Sep |
2 |
| 21 |
19962227 | Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. | 2010 May |
5 |
| 22 |
19450172 | Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. | 2009 May |
1 |
| 23 |
19602868 | Degarelix: a new approach for the treatment of prostate cancer. | 2009 |
2 |
| 24 |
19747011 | Degarelix. | 2009 Oct 1 |
2 |
| 25 |
20110043 | Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. | 2009 |
1 |
| 26 |
18538469 | Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. | 2008 Oct |
2 |
| 27 |
18801505 | A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. | 2008 Nov |
2 |
| 28 |
19035858 | The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. | 2008 Dec |
2 |